Our study found that the serum Wnt5a protein level of newly diagnosed type 2 diabetes patients was significantly increased after the intervention of the glucagon-like peptide-1 receptor agonist compared with before treatment, and the antagonist Sfrp5 was lower than that of the control group. The gene discussed is WNT5A; the disease is type 2 diabetes mellitus.